Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
RESEARCH TOOLSreports
COLL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.39 - $42.29
Previous CloseN/A
Volume233.62K
Average Volume (3M)384.10K
Market Cap
$958.15M
Enterprise Value$2.40B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)12.9
Beta0.39
Next Earnings
Feb 27, 2025EPS Estimate
1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.32
Shares Outstanding32,250,237
10 Day Avg. Volume273,123
30 Day Avg. Volume384,101
Standard Deviation0.12
R-Squared0.13
Alpha0.00508
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.11
Price to Cash Flow (P/CF)-18.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.36
Enterprise Value/Ebitda6.92
Forecast
1Y Price Target
$44.00Price Target Upside47.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Collegium Pharmaceutical News
PremiumCompany Announcements
Collegium Pharmaceutical Expands Board with Nancy Lurker
PremiumCompany Announcements
Collegium Pharmaceutical Unveils 2025 Financial Projections
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCollegium reported record revenue and adj. EBITDA, and announced the appointment of new CEO, Vikram Karnani.
Product GrowthJORNAY PM is projected to exceed $135M, which is estimated to be over 32% pro forma year-over-year growth.
Stock BuybackThe company announced it repurchased another $25M in stock, signaling management confidence.
Bears Say
Market PositionAnother plan will downgrade both Xtampza and Belbuca to parity positions.
Valuation ConcernsThe company's valuation does not fully reflect its top-line growth, profitability, and cash-flow generation, which have been enhanced by the addition of Jornay PM.
---
Ownership Overview
4.44% Insiders
37.98% Mutual Funds
0.90% Other Institutional Investors
24.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
COLL FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was $28.39 and its highest was $42.29 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is $958.15M.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Nov 07, 2024. The company reported $1.61 earnings per share for the quarter, beating the consensus estimate of $1.591 by $0.019.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.54.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,250,237 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of $1.61 in its last earnings report, beating expectations of $1.591. Following the earnings report the stock price went down -7.347%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in COLL
---
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.00 (47.90% Upside)
$44.00 (47.90% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.19%
12-Months-Change
Fundamentals
Return on Equity
42.89%
Trailing 12-Months
Asset Growth
38.86%
Trailing 12-Months
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
---
COLL Company Deck
---
COLL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook, showcasing strong revenue growth and successful integration of the Ironshore acquisition, along with strategic wins in commercial coverage. However, challenges such as the decline in Nucynta revenue and anticipated prescription pressure from formulary removals were noted. Despite these challenges, the company's strategic growth initiatives and robust financial performance indicate a positive sentiment.Read More>---
COLL Stock 12 Month Forecast
Average Price Target
$44.00
▲(47.90% Upside)
Technical Analysis
Best Analysts Covering COLL
1 Year
1 Year Success Rate
15/33 ratings generated profit
1 Year Average Return
+6.73%
upgraded a buy rating last month
Copying Serge Belanger's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +6.73% per trade.
---